53 articles - From Friday Dec 02 2022 to Friday Dec 09 2022
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Lancet |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Intern Med |
Comparative Effectiveness of Team-Based Care With and Without Clinical Decision Support System for Diabetes Management : A Cluster Randomized Trial. Compared with team-based care alone, team-based care with a CDSS significantly reduced cardiovascular risk factors in patients with diabetes, but the effect was modest. Primary funding source Xiamen Municipal Health Commission. |
Long-Term Stability of Coverage Among Michigan Medicaid Beneficiaries : A Cohort Study. For many beneficiaries, Medicaid has served as their primary source of coverage for at least a decade. This pattern would justify increasing investments in the program to improve long-term health outcomes. Primary funding source Self-funded. |
| N Engl J Med |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age. (Funded by the Netherlands Organization for Health Research and Development and the Belgian Health Care Knowledge Center; BeNeDuctus ClinicalTrials.gov number, NCT02884219; EudraCT number, 2017-001376-28.). |
Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. The avoidance of systematic biopsy in favor of MRI-directed targeted biopsy for screening and early detection in persons with elevated PSA levels reduced the risk of overdiagnosis by half at the cost of delaying detection of intermediate-risk tumors in a small proportion of patients. (Funded by Karin and Christer Johansson's Foundation and others; GÖTEBORG-2 ISRCTN Registry number, ISRCTN94604465.). |
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.). |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Lancet |
| N Engl J Med |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Ann Intern Med |
| Lancet |
| N Engl J Med |
Letters to the editors and authors’ replies
| Lancet |
| N Engl J Med |